Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00197132 |
Fluid management study in patients with insulin resistance.
Condition | Intervention | Phase |
---|---|---|
Insulin Resistance |
Drug: Avandia |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety Study |
Official Title: | A Single-Centre, Randomised, Double-Blind, Placebo Controlled, Two 12 Week Period, Cross-Over Phase III Study to Investigate the Effect of Rosiglitazone 4mg Bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects. |
Estimated Enrollment: | 18 |
Study Start Date: | October 2002 |
Ages Eligible for Study: | 30 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 49653/375 |
Study First Received: | September 14, 2005 |
Last Updated: | September 14, 2005 |
ClinicalTrials.gov Identifier: | NCT00197132 History of Changes |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Insulin resistance vasodilatory response |
Obesity Hyperinsulinism Vasodilator Agents Metabolic Diseases Insulin Resistance |
Glucose Metabolism Disorders Rosiglitazone Metabolic Disorder Insulin |
Hyperinsulinism Metabolic Diseases Insulin Resistance Glucose Metabolism Disorders |